This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Sulprostone is a prostaglandin analogue used to treat post-partum hemorrhaging, induce medical abortion, and induce labour in instances of in utero fetal death.
- Generic Name
- Sulprostone
- DrugBank Accession Number
- DB12708
- Background
Sulprostone has been used in trials studying Abortion, Induced.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Sulprostone (DB12708)
- Weight
- Average: 465.56
Monoisotopic: 465.182123516 - Chemical Formula
- C23H31NO7S
- Synonyms
- Sulprostone
- External IDs
- CP-34,089
- CP-34089
- ZK 57 671
- ZK-57671
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareCarboprost tromethamine Carboprost tromethamine may increase the uterotonic activities of Sulprostone. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- G02AD05 — Sulprostone
- Drug Categories
- Abortifacient Agents
- Abortifacient Agents, Nonsteroidal
- Autacoids
- Biological Factors
- Contraceptive Agents, Hormonal
- Eicosanoids
- Fatty Acids
- Fatty Acids, Unsaturated
- Genito Urinary System and Sex Hormones
- Inflammation Mediators
- Lipids
- Menstruation-Inducing Agents
- Prostaglandins
- Prostaglandins E
- Reproductive Control Agents
- Uterotonic agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- Sub Class
- Eicosanoids
- Direct Parent
- Prostaglandins and related compounds
- Alternative Parents
- Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Cyclopentanols / Organosulfonic acids and derivatives / Aminosulfonyl compounds / Cyclic ketones / Cyclic alcohols and derivatives / Carboxylic acids and derivatives / Organopnictogen compounds show 3 more
- Substituents
- Alcohol / Alkyl aryl ether / Aminosulfonyl compound / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxylic acid derivative / Cyclic alcohol / Cyclic ketone / Cyclopentanol show 18 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 501Q5EQ1GM
- CAS number
- 60325-46-4
- InChI Key
- UQZVCDCIMBLVNR-TWYODKAFSA-N
- InChI
- InChI=1S/C23H31NO7S/c1-32(29,30)24-23(28)12-8-3-2-7-11-19-20(22(27)15-21(19)26)14-13-17(25)16-31-18-9-5-4-6-10-18/h2,4-7,9-10,13-14,17,19-20,22,25,27H,3,8,11-12,15-16H2,1H3,(H,24,28)/b7-2-,14-13+/t17-,19-,20-,22-/m1/s1
- IUPAC Name
- (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3R)-3-hydroxy-4-phenoxybut-1-en-1-yl]-5-oxocyclopentyl]-N-methanesulfonylhept-5-enamide
- SMILES
- CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O
References
- General References
- AIFA Product Information: Nalador (sulprostone) powder for solution for infusion [Link]
- External Links
- PubChem Compound
- 5312153
- PubChem Substance
- 347828906
- ChemSpider
- 4471583
- ChEBI
- 135755
- ChEMBL
- CHEMBL1472830
- ZINC
- ZINC000004474665
- Wikipedia
- Sulprostone
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count Not Available Unknown Status Not Available Medically induced abortion 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intravenous 0.5 MG Powder 0.5 mg/1ampoule Powder, for solution Intravenous 500 mcg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0296 mg/mL ALOGPS logP 1.97 ALOGPS logP 1.33 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 4.08 Chemaxon pKa (Strongest Basic) -2.9 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 130 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 121.9 m3·mol-1 Chemaxon Polarizability 48.36 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 23:42 / Updated at June 08, 2021 11:32